David Shaw’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-7,693
| Closed | -$452K | – | 4907 |
|
|
2023
Q4 | $452K | Sell |
7,693
-131,920
| -94% | -$7.42M | ﹤0.01% | 3556 |
|
|
2023
Q3 | $6.08M | Sell |
139,613
-123,325
| -47% | -$4.4M | 0.01% | 1655 |
|
|
2023
Q2 | $9.5M | Buy |
262,938
+17,352
| +7% | +$715K | 0.01% | 1383 |
|
|
2023
Q1 | $9.13M | Buy |
245,586
+32,285
| +15% | +$1.45M | 0.01% | 1450 |
|
|
2022
Q4 | $9.66M | Sell |
213,301
-353,129
| -62% | -$22.9M | 0.01% | 1461 |
|
|
2022
Q3 | $39.6M | Buy |
566,430
+249,522
| +79% | +$18.5M | 0.05% | 487 |
|
|
2022
Q2 | $21.3M | Buy |
+316,908
| New | +$20.2M | 0.02% | 830 |
|
|
2022
Q1 | – | Sell |
-2,716
| Closed | -$398K | – | 6088 |
|
|
2021
Q4 | $398K | Sell |
2,716
-9,592
| -78% | -$1.49M | ﹤0.01% | 4532 |
|
|
2021
Q3 | $2.18M | Sell |
12,308
-105,339
| -90% | -$16.9M | ﹤0.01% | 2960 |
|
|
2021
Q2 | $19M | Buy |
117,647
+35,725
| +44% | +$5.74M | 0.02% | 1047 |
|
|
2021
Q1 | $14M | Buy |
81,922
+18,660
| +29% | +$3.69M | 0.01% | 1151 |
|
|
2020
Q4 | $13.9M | Buy |
63,262
+27,897
| +79% | +$6.03M | 0.01% | 1174 |
|
|
2020
Q3 | $5.87M | Buy |
+35,365
| New | +$4.84M | 0.01% | 1582 |
|
|
2019
Q2 | – | Sell |
-3,763
| Closed | -$293K | – | 3933 |
|
|
2019
Q1 | $276K | Sell |
3,763
-12,462
| -77% | -$848K | ﹤0.01% | 3257 |
|
|
2018
Q4 | $688K | Sell |
16,225
-43,520
| -73% | -$1.73M | ﹤0.01% | 2902 |
|
|
2018
Q3 | $2.81M | Sell |
59,745
-145,601
| -71% | -$8.11M | ﹤0.01% | 1961 |
|
|
2018
Q2 | $10.1M | Sell |
205,346
-78,745
| -28% | -$2.97M | 0.01% | 1071 |
|
|
2018
Q1 | $8.72M | Sell |
284,091
-194,392
| -41% | -$5.4M | 0.01% | 1077 |
|
|
2017
Q4 | $8.73M | Sell |
478,483
-98,599
| -17% | -$1.53M | 0.01% | 1116 |
|
|
2017
Q3 | $6.75M | Buy |
577,082
+495,915
| +611% | +$2.87M | 0.01% | 1175 |
|
|
2017
Q2 | $296K | Buy |
81,167
+33,653
| +71% | +$129K | ﹤0.01% | 3035 |
|
|
2017
Q1 | $247K | Sell |
47,514
-2,601
| -5% | -$14.3K | ﹤0.01% | 3044 |
|
|
2016
Q4 | $238K | Buy |
50,115
+39,138
| +357% | +$213K | ﹤0.01% | 3212 |
|
|
2016
Q3 | $73K | Buy |
+10,977
| New | +$58.4K | ﹤0.01% | 3309 |
|
|
2015
Q4 | – | Sell |
-10,650
| Closed | -$367K | – | 4013 |
|
|
2015
Q3 | $367K | Buy |
+10,650
| New | +$322K | ﹤0.01% | 3249 |
|
Other funds holding MRTX
David Shaw's MRTX Position: Q1 2024 in Review
David Shaw sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 7,693 shares — an estimated $452K sold.
David Shaw first reported a position in MRTX in Q3 2015 and held it in 25 quarters. The position peaked at $39.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- David Shaw reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- David Shaw sold 7,693 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $452K.
- David Shaw first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 25 quarters.
- David Shaw's Mirati Therapeutics, Inc. Common Stock position peaked at $39.6M in Q3 2022.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.